Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System

Esketamine was approved for the treatment of treatment-resistant depression in 2019. After the approval of esketamine, numerous concerns have been raised regarding its long-term safety and tolerability. A previous systematic pharmacovigilance study on esketamine-related adverse events (AEs) was publ...

Full description

Bibliographic Details
Main Authors: Haoning Guo, Bin Wang, Shuying Yuan, Silin Wu, Jing Liu, Miaoquan He, Jisheng Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Pharmacology
Subjects:
esketamine
pharmacovigilance
neurological adverse events
signal
FAERS
disproportionality analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.849758/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.849758/full

Similar Items